Lifecare ASA
Sector unknown·LIFE · Oslo Børs·Fiscal year to 31/12/2024
Exposure profile
Derived from what the company itself writes. Empty directions mean the report doesn't mention themes of that type.
In their own words
Grouped by theme, from the management review in the annual report. A · The company itself is a verbatim quote, B · From the report is without a verified quote.
Diabetes care
Technology
StrategyPositive impact: strengthens
“In 2024, we filed a new European patent for sensor technology that could be used to monitor additional health conditions, including cardiovascular and immune disorders.””
Annual report 2024A · The company itself
Market
“Lifecare’s focus is to bring the next generation of Continuous Glucose Monitoring (CGM) systems to market.”
Annual report 2024A · The company itself
Market
“Our focus is on revolutionizing glucose monitoring with the Sencell sensor technology, which uses osmotic pressure to offer continuous glucose monitoring (CGM) with extended wear times, greater comfort, and improved glucose management.”
Annual report 2024A · The company itself
Market
“Scientific risk Lifecare develops technology for sensing and monitoring various body analytes, using osmotic pressure sensors to detect variations in analyte levels.”
Annual report 2024A · The company itself
Market
“Currently, only about 50% of diabetes cases are diagnosed, and one-third of those diagnosed require glucose monitoring. As a result, in 2021, the global potential patient group for glucose monitoring was approximately 90 million people—a figure that grows.”
Annual report 2024A · The company itself
Automation and robotics
Technology
StrategyPositive impact: strengthens
“We have made great strides in developing our glucose sensor, preparing for large-scale manufacturing, strengthening our organization, and moving closer to commercialization. One key milestone was the successful pilot production of our Sencell sensor.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“We have established a pilot production line and automated critical stages of the production process, marking a significant step toward full automation. In 2025, we will open a large-scale production facility in Mainz, Germany.”
Annual report 2024A · The company itself
Animal diseases and biosecurity
Macro
StrategyPositive impact: strengthens
“As we prepare for regulatory studies and finalize our product for the human market, we are also targeting a launch in the veterinary market, where regulations are less stringent. This approach will allow us to gain valuable product experience, which will inform and strengthen our strategy for entering the human market.”
Annual report 2024A · The company itself
Artificial intelligence
Technology
StrategyPositive impact: strengthens
“We have formed a collaboration with OneTwo Analytics AB, a leader in diabetes data analytics. This partnership provides Lifecare access to OneTwo’s AI and machine learning-based software for self-monitoring and automatic interpretation of CGM data.”
Annual report 2024A · The company itself
Chains out: this strengthens Data centres, strengthens Semiconductors and electronic components, strengthens Semiconductor industry
Rare earths and critical raw materials
Raw materials and inputs
Market
“Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.”
Annual report 2024A · The company itself
Chains in: Wind power strengthens
Equity and capital markets
Macro
DriverPositive impact: strengthens
“The liquidity situation at year end is satisfactory, with moderate to high risk as Lifecare is still dependent on financing. Financing risk In 2024, Lifecare successfully completed a rights issue and a public retail offering, raising gross proceeds of NOK 106.6 million.”
Annual report 2024A · The company itself
Financial regulation
Regulation
DriverNegative impact: weakens
“Since Lifecare prioritizes commercialization in Europe, the device must comply with the EU Medical Device Regulation (MDR). Regulatory bodies require clinical evidence demonstrating that Sencell provides accurate glucose monitoring, reliability, and long-term safety.”
Annual report 2024A · The company itself
Cybersecurity (products and services)
Technology
DriverNegative impact: weakens
“Cybersecurity risk Lifecare maintains a robust information security program to safeguard data confidentiality, integrity, and availability. Through advanced security protocols, continuous monitoring, and regular employee training, Lifecare proactively mitigates threats and strengthens defenses across the organization.”
Annual report 2024A · The company itself
Chains in: Cyber attacks and IT security risk strengthens
Chains out: this strengthens Digitalisation
Medical devices
Technology
InputNegative impact: weakens
“To support this, we have partnered with TTP plc (The Technology Partnership), a global expert in medical implants and sensors. This collaboration will help us refine our prototype, improving Successful Sencell pilot production Chemistry breakthrough improved glucose sensitivity Read more Read more both product performance and production efficiency.”
Annual report 2024A · The company itself
Chains in: Ageing population strengthens
Other currencies
Macro
DriverNegative impact: weakens
“In particular, fluctuations in the Euro affect the Group, as a majority of its suppliers invoice in Euros while most cash is held in Norwegian Kroner. Currently, no currency hedging strategy is employed to mitigate these fluctuations.”
Annual report 2024A · The company itself
Europe
Geography
Geography
“Lifecare is headquartered in Bergen, Norway, with research and development activities and production facilities in Mainz and Reutlingen, Germany.”
Annual report 2024A · The company itself
Geography
“Lifecare’s main suppliers and partners are based in Europe, and plans to commercialize its product primarily in the European market.”
Annual report 2024A · The company itself
Denmark
Geography
Geography
“Lifecare is headquartered in Bergen, Norway, with research and development activities and production facilities in Mainz and Reutlingen, Germany. Our chemistry lab operates in Bristol, UK.”
Annual report 2024A · The company itself
Labour and wages
Raw materials and inputs
InputNegative impact: weakens
“Lifecare Group employed 39 individuals, including part-time staff, equating to 33 full-time equivalents (FTEs).”
Annual report 2024A · The company itself
Competitors mentioned in the report
No named competitors in the report.
Financial figures
| Revenue latest fiscal year | 0 bn NOK |
| Revenue growth vs. the year before, same method | -28.9 % |
| EBITDA reported by the company | -0.08 bn NOK |
| Net debt debt incl. leasing minus cash | N/A |
| Diluted EPS per share | -5.73 NOK |
Source: annual report (ESEF) A. See the report
Criteria
| Profit | ✗ |
| Growing | ✗ |
| Healthy balance sheet | N/A |
Only the criteria that can be computed from financial statements on this page. The remaining criteria (such as price and dividend) need a share price and are in the analysis.
Figures are in the report's currency (NOK), not converted to DKK. Quotes are shown as the company's own words in the report's original language.